Secondary Objective:~To determine the safety and immunogenicity of P1101 400 μg subcutaneous (SC) single dose + Ribavirin 800-1400 mg PO daily.
Primary Objective:~To determine the P1101 pharmacokinetic (PK) profile at the single dose of 400 μg.